- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07941765
Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults (SAGE UTI)
SAGE-UTI: Standard Culture Versus Advanced Guidance UTI® Testing in Older Adults: a Single-blind Randomized Controlled Trial Evaluating Outcomes in UTI
The goal of this clinical trial is to compare two urine testing methods used to diagnose urinary tract infections (UTIs) in adults aged 60 years and older.
The main question this trial aims to answer is:
Does Guidance® UTI testing, compared with standard urine culture, improve patient outcomes and help healthcare providers make more appropriate antibiotic treatment decisions?
Participants will:
- Be randomly assigned to either Guidance UTI testing or standard urine culture testing.
- Provide a urine sample during their initial clinic visit.
- Complete questionnaires at the initial visit and approximately 14 and 28 days later.
Researchers will compare UTI-related repeat medical visits, emergency care, hospitalizations, new UTI diagnoses, and antibiotic treatment decisions between the two groups.
연구 개요
상태
상세 설명
**Background and Rationale**
Urinary tract infections (UTIs) are common among older adults, particularly those with recurrent infections or underlying urinary tract conditions. Standard urine culture has limitations, including delayed results, incomplete detection of certain pathogens, and challenges identifying infections involving multiple organisms. These limitations may contribute to empiric antibiotic prescribing, inappropriate treatment, and adverse clinical outcomes.
Guidance® UTI combines multiplex polymerase chain reaction (M-PCR) for microbial identification and resistance gene detection with pooled antibiotic susceptibility testing (P-AST). This approach provides microbial identification and antibiotic susceptibility results within approximately 48 hours of laboratory receipt.
**Trial Design**
SAGE-UTI is a prospective, multicenter, single-blind, randomized controlled trial comparing Guidance UTI testing with standard urine culture in adults aged 60 years and older presenting with suspected UTIs.
Following informed consent and confirmation of eligibility, participants will be randomized in a 1:1 ratio to one of two diagnostic testing pathways:
- **Arm A - Guidance UTI:** Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing.
- **Arm B - Standard Urine Culture:** Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice.
All urine specimens will be processed at the Pathnostics central laboratory. Treating clinicians will receive results corresponding to the assigned diagnostic pathway and will make antibiotic treatment decisions based on clinical judgment and routine practice. Results from the alternative testing pathway will remain blinded unless disclosure is medically necessary for participant safety or appropriate clinical management.
**Trial Procedures**
Participants will undergo a baseline clinical assessment, urine specimen collection, and documentation of relevant medical history, symptoms, and antibiotic treatment.
Treating clinicians will complete a treatment decision survey following review of the assigned diagnostic results. Participants will complete follow-up assessments at approximately Days 14 and 28 to document clinical outcomes and UTI-related healthcare utilization.
Residual urine specimens will also be evaluated for exploratory urinary biomarkers, including interleukin-1 beta (IL-1β), interleukin-8 (IL-8), and neutrophil gelatinase-associated lipocalin (NGAL), to explore their relationship with diagnostic findings and clinical outcomes. These exploratory results will not be reported to treating clinicians.
**Clinical Significance**
The trial will evaluate whether Guidance UTI testing, compared with standard urine culture, improves clinical outcomes and supports more appropriate antibiotic prescribing in older adults with suspected UTIs. The findings may help inform diagnostic testing strategies, improve UTI management, and support antimicrobial stewardship.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Darshika Mistry
- 전화번호: 6482844874
- 이메일: dmistry@pathnostics.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Individuals ≥ 60 years old requiring evaluation for suspected urinary tract infection, whose clinical management will be impacted by the provided results, seen in outpatient urology or urogynecology specialty practice
설명
nclusion Criteria:
- Able to provide written informed consent
- Male and female subjects ≥ 60 may participate with no predetermined quotas or ratios for gender participation.
- A history of (at least one): a) recurrent UTIs (defined as ≥ 2 UTIs within a 6 month period in the last 12 months) b) urinary tract obstruction (including urinary retention or hydronephrosis) and/or urinary tract injury (i.e. nephrolithiasis, ureteral or urinary stent placement, or any urologic surgery or instrumented procedure) within the last 24 months
- Must present at the time of enrollment with clinically suspected active UTI (any lower urinary tract symptoms)
- Must have positive chemical (dipstick) urinalysis (defined as nitrite "positive" and/or leukocyte esterase > "trace" by chemical urinalysis) performed at the baseline (Day 1) visit.
- Management requires microbial identification and antibiotic sensitivities from urine
- Able to provide a urine specimen (midstream voided or catheter collected)
Exclusion Criteria:
- Subjects with indwelling catheter (suprapubic or foley) or are chronically reliant on intermittent self-catheterization
- Subjects with suspected pyelonephritis, febrile UTI, or bacteremic UTI (as indicated by one or more of the following symptoms: fever, chills, rigors, hemodynamic instability, flank pain, costovertebral angle tenderness)
- Subjects with suspected prostatitis (presence of tender, enlarged, or boggy prostate on digital rectal examination; history of prostate biopsy or surgery in previous 30 days)
- Currently receiving radiation therapy in the pelvic region
- Subjects with history of unstable, untreated, or are failing treatment for overactive bladder (either neurogenic or non-neurogenic)
- Subjects with history of bladder malignancy in the past 3 years
- Subjects that have been treated with chemotherapy in the past 3 years
- Inability to independently complete subject surveys (i.e. unable to read or hear survey questions and respond appropriately)
- Incarceration
- Pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
|---|
|
Arm A - Guidance UTI
Urine specimens will undergo molecular microbial identification and pooled antibiotic susceptibility testing. |
|
Arm B - Standard Urine Culture:
Urine specimens will undergo standard urine culture and antibiotic susceptibility testing, as available, according to routine clinical practice. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent difference between diagnostic test arm in the number of composite negative outcomes
기간: 28 days
|
Percent difference between diagnostic test arm in the number of composite negative outcomes (e.g., return visit to provider for UTI, ER visit for UTI, urgent care visit for UTI, hospitalization for UTI, new UTI diagnosis) |
28 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent difference between diagnostic test arm in: • The number of adverse events • The number of subjects empirically treated • The number of changes to antibiotic(s) prescribed
기간: 28 days
|
Percent difference between diagnostic test arm in:
|
28 days
|
|
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject
기간: 28 days
|
Differences in microbial identification, quantitation, and antibiotic susceptibility results between the two test results for the same subject |
28 days
|
|
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s)
기간: 28 days
|
Percentage of directed antibiotic prescriptions that are concordant with susceptibility testing result(s) |
28 days
|
|
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions
기간: 28 days
|
Relative frequency with which result components and other factors are reported to influence antibiotic prescribing decisions |
28 days
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2026-SAGE-UTI
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .